Incretin Therapies Linked to Lower Alcohol Use Risk After Bariatric Surgery

The employ of incretin-based therapies following bariatric surgery appears to be associated with a significantly lower risk of developing alcohol use disorder (AUD), according to a retrospective analysis published in March 2026. The study, conducted by researchers at Virginia Commonwealth University, suggests a potential benefit of these medications—increasingly used after surgery for weight loss maintenance—in mitigating a known risk associated with bariatric procedures.

Bariatric Surgery and Alcohol Use Risk

Bariatric surgery, while effective for weight loss, has been linked to an increased risk of substance use disorders, including AUD. This phenomenon isn’t fully understood, but theories suggest changes in gut hormones and brain reward pathways following surgery may play a role. Bariatric surgery alters the body’s metabolism and hormonal signals and these changes can sometimes lead to increased vulnerability to addictive behaviors.

Incretin-based therapies (IBTs), such as semaglutide, liraglutide, and tirzepatide, are medications originally developed to treat type 2 diabetes. They work by mimicking the effects of incretin hormones, which regulate insulin release and appetite. Increasingly, these drugs are prescribed after bariatric surgery to help patients manage weight regain or inadequate initial weight loss. Recent research also indicates that IBTs may influence reward pathways in the brain, potentially impacting addictive behaviors. Alcohol use disorder (AUD) is a medical condition characterized by an inability to control alcohol consumption, despite adverse consequences.

Study Findings: Lower AUD Incidence with IBTs

The retrospective analysis, involving over 15,000 adults who underwent bariatric surgery and subsequently received anti-obesity medications, compared outcomes between those prescribed IBTs and those prescribed non-IBT medications. The study found that patients receiving IBTs had a 55% lower risk of new-onset AUD (2.4 per 1,000 person-years versus 5.2 per 1,000 person-years) compared to those receiving other anti-obesity medications. The IBT group also exhibited a 41% reduced risk of initiating medications for AUD (15.2 vs. 25.6 per 1,000 person-years).

The study population comprised 11,194 patients receiving IBTs and 4,188 receiving non-IBTs. Researchers used propensity score matching to create comparable cohorts, accounting for potential differences in baseline characteristics. Follow-up duration extended up to two years after initiating anti-obesity medications. Non-IBT medications included orlistat, phentermine, low-dose naltrexone, benzphetamine, phendimetrazine and diethylpropion.

What the Research Doesn’t Tell Us

It’s crucial to understand that this study demonstrates an association, not causation. While the findings suggest a link between IBT use and reduced AUD risk, they do not prove that IBTs directly prevent alcohol use disorder. Other factors, such as differences in patient demographics or lifestyle, could contribute to the observed results. The retrospective nature of the study also introduces the possibility of unmeasured confounders – variables that were not accounted for in the analysis but could influence the outcome.

Specifically, the researchers acknowledge limitations related to the lack of detailed data on alcohol consumption patterns, such as quantity and frequency of binge drinking. The relatively short follow-up period (up to two years) also limits the ability to assess long-term effects. The study population was also not fully representative of all bariatric surgery patients, with a higher proportion of women in both groups.

Implications for Post-Bariatric Care

Juan Pablo Arab, MD, associate professor of medicine at Virginia Commonwealth University School of Medicine, emphasized the importance of these findings in the context of post-bariatric care. “After bariatric surgery, many patients do incredibly well metabolically, but we also see a real and clinically important rise in alcohol-related risk in a subset,” he stated. “At the same time, incretin-based therapies are being used more and more after surgery for inadequate weight loss or weight regain, and there is growing interest that these drugs may affect reward pathways, not just weight.”

These findings underscore the need for routine screening for alcohol misuse following bariatric surgery. Early identification and intervention are critical for preventing the development of AUD. While IBTs may offer a potential protective effect, they should not be considered a substitute for comprehensive behavioral counseling and support services. Alcohol misuse remains a significant public health concern, and a multifaceted approach is essential for addressing this issue.

Ongoing Research and Future Directions

Dr. Arab notes that prospective studies are needed to confirm these findings and to elucidate the underlying mechanisms by which IBTs may influence alcohol-related behaviors. Future research should also investigate the optimal dosage and duration of IBT treatment for reducing AUD risk in post-bariatric patients. Researchers are also exploring the potential of IBTs as a treatment for AUD in individuals who have not undergone bariatric surgery.

The Supreme Court of Georgia recently issued an email scam alert, warning the public about fraudulent emails impersonating court staff. This serves as a reminder to be vigilant about potential scams and to verify the authenticity of any unsolicited communications. The Wappinger Town issued a scam email alert on March 2, 2026, highlighting the increasing prevalence of such schemes. A cybersecurity expert also recently warned of a new calendar scam that could result in significant financial losses.

For now, the focus remains on providing comprehensive post-bariatric care, including routine screening for substance use disorders and offering appropriate support and treatment options. Patients should discuss any concerns about alcohol use with their healthcare providers.

Juan Pablo Arab, MD, can be reached at [email protected].